AllAfrica on MSN
Ivanhoe /HPX U.S.$2.8 Bn Deal Faces Setbacks
The Ivanhoe Atlantic/HPX concession faces significant hurdles due to the lack of formal Guinean approval and unresolved issues regarding third-party rail access, particularly the involvement of AML.By ...
Compared with white patients, Black patients with an aggressive form of leukemia—called acute myeloid leukemia (AML)—were on ...
Compared with white patients, Black patients with an aggressive form of leukemia--called acute myeloid leukemia (AML)--were ...
The mortality-to-incidence ratio initially increased in the early 2000s, declined sharply between 2008 and 2011, and remained stable thereafter.
Summary • Curis, Inc. stock jumped 8.6% in after-hours trading to $1.26 after positive clinical trial results for its AML treatment.• 62.5% of patients in the frontline study achieved undetectable ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients with AML, ALL and MDS compared to a conventional allogeneic hematopoietic stem cell ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...
In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results